Poor
Mostly Aligned
Patient Risk:
Medium
Summary
Multiple core product/dosing characteristics in the claims are unsupported by the supplied label sections (notably extended-release and release-pattern-aligned dosing), and several safety/side-effect statements are unsupported.
Category Scores
Accurate Statements
Gralise is used for treating nerve pain, specifically postherpetic neuralgia.
Supported by 1 INDICATIONS AND USAGE.
Gralise contains gabapentin.
Supported by 11 DESCRIPTION.
The main approved use of Gralise is postherpetic neuralgia.
Supported by 1 INDICATIONS AND USAGE.
Gralise is not the same as gabapentin immediate-release products.
Supported by 1 INDICATIONS AND USAGE (not substitutable due to differing pharmacokinetic profiles).
Gralise is not approved for all types of pain.
Partially supported by 1 INDICATIONS AND USAGE (label indication limited to postherpetic neuralgia).
Switching between Gralise and other gabapentin formulations usually requires guidance because dosing and release characteristics differ.
Supported by 1 INDICATIONS AND USAGE; 2 DOSAGE AND ADMINISTRATION; 17 PATIENT COUNSELING INFORMATION.
Gralise is often taken once daily in the evening, depending on the prescriber’s instructions.
Partially supported by 2 DOSAGE AND ADMINISTRATION (titrated to once daily with the evening meal).
Unsupported Statements
Gralise is a prescription medicine in the gabapentin family.
Not supported by any provided label section in the supplied dataset.
That action helps reduce signals that cause chronic nerve pain.
The provided label text does not support this specific mechanistic/consequence wording.
Gralise is formulated as an extended-release product.
No provided label section in the dataset explicitly supports “extended-release” wording.
Gralise is designed to be taken with a dosing schedule that fits the medication’s release pattern.
No provided label section supports the “release pattern” framing.
Common side effects for gabapentin-type medicines can include dizziness.
No provided label section in the dataset lists this as a common side effect for gabapentin/Gralise.
Common side effects for gabapentin-type medicines can include sleepiness.
No provided label section in the dataset supports this as a common side effect.
Common side effects for gabapentin-type medicines can include coordination problems.
No provided label section in the dataset supports this as a common side effect.
Serious reactions with gabapentin-type medicines are less common.
No provided label section in the dataset supports relative frequency (“less common”).
Serious reactions require urgent medical attention if they occur.
No provided label section in the dataset supports this general urgency statement.
Gralise is a branded extended-release gabapentin product.
No provided label section in the dataset explicitly supports “extended-release” wording.
Contradictions
Important Omissions
Dose titration details (e.g., titration schedule and target dose of 1,800 mg once daily) and tablet swallowing instructions (swallow whole; do not split/crush/chew).
Importance:
Moderate
Label statements that GRALISE should not be substituted with other gabapentin products due to differing pharmacokinetic profiles (and that reduced/discontinued/substituted dosing should be gradual over at least one week).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported or vague claims about extended-release/release-pattern dosing increase the risk of incorrect administration framing; multiple safety/side-effect assertions are also unsupported by the provided label sections.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several core product and administration/release-related claims are unsupported by the supplied label sections (including explicit “extended-release” and release-pattern dosing alignment). Several adverse-effect statements are also unsupported.
Suggested Improvement
Restrict claims to the supplied label text, explicitly cite 2 DOSAGE AND ADMINISTRATION for administration/timing and discontinuation/substitution guidance, and avoid general “common side effects” and “serious reactions urgency/frequency” statements unless present in the provided label sections.